“Digital therapeutics” startups are starting to win more respect-and investment dollars-from pharmaceutical giants. But the two sides are still figuring out how to work together to capitalize on the potential for apps, devices, and other software-enabled technologies to impact patients’ health.
That’s what stood out to me the most as I listened to leaders from some of the world’s largest life sciences companies-Novartis (NYSE: NVS), Sanofi (NYSE: SNY), AstraZeneca (NYSE: AZN), and Johnson & Johnson (NYSE: JNJ)-talk about their firms’ interest in the nascent field of digital medicine at an industry conference, DTxDM East, held at… Read more »
UNDERWRITERS AND PARTNERS